OUR PORTFOLIO

The current portfolio comprises 13 companies: NeuroAdjuvants, Sera Prognostics, ContraDyn, MedCatheters, Q Therapeutics, Elute, XableCath, MedAnalytics, JST Research, Veritract, Complexa, PhotoPharmics and Catheter Connections.

Current Investments

Past Investments